Hub Genes and Therapeutic Pathways of CTRP9 in Cardiac Ischemia/Reperfusion Injury: A Bioinformatics Perspective

Background: Ischemia/reperfusion injury (IRI) is a significant contributor to cardiac morbidity, while therapeutic options remain limited. According to previous evidence, C1q/TNF-related protein 9 (CTRP9), an adipokine with cardiometabolic regulatory properties, may serve as a potential modulator of myocardial injury. In this study, comprehensive bioinformatics analyses were primarily employed to identify hub genes and elucidate key therapeutic pathways associated with CTRP9 in the context of IRI. Methods: An interrelation analysis of hub genes was conducted to identify direct and indirect interactions. The resulting network and enrichment data were extracted from Cytoscape-GeneMANIA3.6.0, based on a genome-wide human interaction map, for further analysis and visualization. Results: Protein-protein interaction networks and functional enrichment analyses revealed that CTRP9 exerts cardioprotective effects primarily through the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which leads to reduced cardiomyocyte apoptosis and enhanced angiogenesis. Notably, bioinformatics data suggested several downstream effectors, such as ucp1, gsk3b, and rps6kb1, as well as collagen-related genes (i.e., col4a2, col14a1, and col18a1), linked to the beneficial effects of CTRP9, considering it a promising therapeutic option related to IRI. Conclusion: These findings recommend several hub genes and pathways that may serve as novel therapeutic targets, highlighting the potential of CTRP9-based interventions for managing IRI-induced cardiac damage and improving clinical outcomes, particularly in cases of myocardial damage caused by IRI. Uncovering all possible underlying mechanisms could enhance our ability to better address the pathological sequelae following IRI.